Judith A Fox Selected Research

Neoplasms (Cancer)

10/2022	Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
1/2022	Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
1/2022	Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.
5/2017	Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
9/2016	Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
4/2010	Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
4/2010	Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
9/2009	SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
4/2008	A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
3/2006	Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Judith A Fox Research Topics

Disease

11	Neoplasms (Cancer) 10/2022 - 05/2002
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2018 - 04/2010
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 05/2009
2	Stomatitis 09/2015 - 02/2015
2	Multiple Myeloma 06/2010 - 09/2009
2	Ovarian Neoplasms (Ovarian Cancer) 04/2010 - 04/2010
1	Necrosis 05/2017
1	Glioblastoma (Glioblastoma Multiforme) 05/2017
1	Pneumonia (Pneumonitis) 09/2015
1	Neutropenia 09/2015
1	Sepsis (Septicemia) 09/2015
1	Febrile Neutropenia 09/2015
1	Cardiotoxicity 02/2015
1	Leukemia 10/2010
1	Hypertension (High Blood Pressure) 04/2008
1	Anorexia 04/2008
1	Melanoma (Melanoma, Malignant) 04/2008
1	Reperfusion Injury 01/2002

Drug/Important Bio-Agent (IBA)

8	vosaroxinIBA 11/2018 - 04/2010
6	QuinolonesIBA 05/2017 - 04/2010
5	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2018 - 10/2010
3	vecabrutinibIBA 10/2022 - 01/2022
3	Agammaglobulinaemia Tyrosine KinaseIBA 10/2022 - 01/2022
3	Type II DNA Topoisomerases (Topoisomerase II)IBA 09/2016 - 04/2010
3	N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamideIBA 06/2010 - 05/2009
2	DNA (Deoxyribonucleic Acid)IBA 09/2016 - 02/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2009 - 05/2009
2	Proteins (Proteins, Gene)FDA Link 03/2006 - 05/2002
1	ibrutinibIBA 10/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Temozolomide (Temodar)FDA LinkGeneric 05/2017
1	Gemtuzumab (Mylotarg)FDA Link 12/2016
1	AntigensIBA 12/2016
1	IronIBA 02/2015
1	AnthracyclinesIBA 02/2015
1	PlatinumIBA 04/2010
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 04/2008
1	Alkaline PhosphataseIBA 04/2008
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2008
1	tumor-associated antigen 72IBA 03/2006
1	EpitopesIBA 03/2006
1	ProdrugsIBA 03/2006
1	CarbohydratesIBA 03/2006
1	Death Domain ReceptorsIBA 05/2002
1	LigandsIBA 05/2002
1	Topoisomerase I InhibitorsIBA 05/2002
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2002
1	IntegrinsIBA 01/2002
1	adhesion receptorIBA 01/2002

Therapy/Procedure

1	Immunotherapy 12/2016
1	Therapeutics 04/2010